Christine Dolan
About
Christine Dolan is from Wilmington, North Carolina, United States. Christine works in the following industries: "Biotechnology Research". Christine is currently EVP & COO, Biologics Safety Testing at Maravai LifeSciences. Christine also works as COO at Glen Research, a job Christine has held since Oct 2018. Another title Christine currently holds is COO at Cygnus Technologies, LLC. In Christine's previous role as a SVP Product Development at Catalent Pharma Solutions, Christine worked in until Oct 2017. Prior to joining Catalent Pharma Solutions, Christine was a Vice President, Global Softgel Operations at Catalent Pharma Solutions and held the position of Vice President, Global Softgel Operations. Prior to that, Christine was a Vice President and General Manager, Development and Analytical Solutions at Catalent Pharma Solutions from Jan 2012 to Dec 2013. Christine started working as Vice President, Global Operations at Catalent Pharma Solutions in Development and Clinical Services in Feb 2011. From Feb 2010 to Feb 2011, Christine was General Manager, Sterile Technologies at Catalent Pharma Solutions, based in Woodstock, IL. Prior to that, Christine was a VP, Quality Operations at Catalent Pharma Solutions from Sep 2009 to Feb 2010. Christine started working as Director, Nuclear Operations and Global Quality Control at GE Healthcare in Aug 2008.
Christine Dolan can be found on Finalscout.com, where members can access Christine Dolan's email for free. Finalscout is a professional database with more than 500 million business professional profiles and 200 million company profiles.
Christine Dolan's current jobs
Operational Leadership of Glen Research the newest addition to Maravai LifeSciences
Christine Dolan's past jobs
Appointed Senior Vice President, Product Development in September 2016. Member of the Executive Leadership team; Executive Sponsor of Catalent Women's Network Let the Global Product Development Organization across all technologies and geographies supporting $2B business
In December 2013, Christine was appointed Vice President, Global Softgel Operations Nov 2013 with responsibility for 11 Softgel manufacturing and development sites globally spanning five continents (sites include Australia, Japan, China, Germany, Italy, France, Brazil, Argentina and US) with responsibility for over 3500 employees and a business that generated $900M in revenue
P&L Leader for the Development and Analytical Solutions Business Unit In Feb 2011 upon the completion of the acquisition of the Aptuit Clinical and Development business, the Development and Analytical services Business unit was formed and she was named VPGM for this new BU, which included operations in Kansas City, MO, RTP, NC and Swindon, UK. She led the integration of the businesses, built a European offering in the UK and grew the business year on year >10%.
Jan 2011 was named VP of Operations for the Development and Clinical Services Business, with responsibilities for Clinical sites in Philadelphia, Bolton UK, Shorndorf, Germany; analytical development and services site in RTP, and Biologics development site in Madison Wisc.
Feb 2010 named General Manager for the Woodstock, IL Sterile technologies facility of 650 employees, successfully leading the site to solid regulatory compliance and building a sustainable leadership organization
Leadership of Validation, NPI and QC activities for five global sterile facilites
GE acquired Amersham Health
Leadership of North American Supply Chain, including international nuclear logistics, procurement and and customer service
QC Director (Illinois and New Jersey sites) 2000-2002 QC Manager (Micro, Chemistry, Devices, Raw Materials) 1998-2000 QC Microbiology Supervisor 1995-98